Implantable Cardioverter-Defibrillators in Patients with ESRD: Complications, Management, and Literature Review

Author(s): Bayati Mehdi, Hosseini Kaveh, Vasheghani-Farahani Ali*.

Journal Name: Current Cardiology Reviews

Volume 15 , Issue 3 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Cardiovascular diseases are the leading cause of death among dialysis patients, accounting for about 40% of all their mortalities. Sudden cardiac death (SCD) is culpable for 37.5% of all deaths among patients with end-stage renal disease (ESRD). Implantable cardioverterdefibrillators (ICDs) should be considered in dialysis patients for the primary or secondary prevention of SCD. Recent studies on the implementation of ICD/cardiac resynchronization therapy do not exclude patients with ESRD; however, individualized decisions should be made in this group of patients. A thorough evaluation of the benefits of ICD implementation in patients with ESRD requires several large-scale mortality studies to compare and follow up patients with ESRD with and without ICDs. In the present study, we sought to determine and clarify the complications associated with ICD implementation and management thereof in patients suffering from ESRD.

Methods: To assess the complications allied to the implementation of ICDs and their management in patients with ESRD, we reviewed available related articles in the literature.

Results and Conclusions: ICD implementation in dialysis patients has several complications, which has limited its usage. Based on our literature review, the complications of ICD implementation can be categorized as follows: (1) Related to implantation procedures, hematoma, and pneumothorax; (2) Related to the device/lead such as lead fracture and lead dislodgment; (3) Infection; and (4) Central vein thrombosis. Hence, the management of the complications of ICDs in this specific group of patients is of vital importance.

Keywords: Cardioverter-defibrillators, patients, ESRD, complications, management, literature review.

[1]
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139(2): 137-47.
[2]
Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ Arrhythm Electrophysiol 2010; 3(5): 553-9.
[3]
Genovesi S, Porcu L, Luise MC, et al. Sudden death in end stage renal disease: Comparing hemodialysis versus peritoneal dialysis. Blood Purif 2017; 44(1): 77-88.
[4]
Al-Khatib SM, Yancy CW, Solis P, et al. 2016 AHA/ACC clinical performance and quality measures for prevention of sudden cardiac death. J Am Coll Cardiol 2016; 2016: 23062.
[5]
Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005; 68(2): 818-25.
[6]
Bansal N, Szpiro A, Reynolds K, et al. Long-term outcomes associated with implantable cardioverter defibrillator in adults with chronic kidney disease. JAMA Intern Med 2018; 178(3): 390-8.
[7]
Roberts PR, Green D. Republished article: Arrhythmias in chronic kidney disease. Postgrad Med J 2012; 88(1036): 97-104.
[8]
Cleland JG, Mareev Y. CRT for heart failure and ESRD. J Am Coll Cardiol 2015; 66(23): 2630-2.
[9]
Hager CS, Jain S, Blackwell J, Culp B, Song J, Chiles CD. Effect of renal function on survival after implantable cardioverter defibrillator placement. Am J Cardiol 2010; 106(9): 1297-300.
[10]
El‐Chami MF, Matar L, Smith P, et al. Long‐term survival of implantable cardioverter defibrillator recipients with end‐stage renal disease. J Arrhythm 2017; 33(5): 459-62.
[11]
Cuculich PS, Sánchez J, Kerzner R, et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007; 30(2): 207-13.
[12]
Pun PH, Hellkamp AS, Sanders GD, et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: A matched cohort study. Nephrol Dial Transplant 2015; 30(5): 829-35.
[13]
Amin MS, Fox AD, Kalahasty G, Shepard RK, Wood MA, Ellenbogen KA. Benefit of primary prevention implantable cardioverter‐defibrillators in the setting of chronic kidney disease: A decision model analysis. J Cardiovasc Electrophysiol 2008; 19(12): 1275-80.
[14]
Hiremath S, Punnam SR, Brar SS, et al. Implantable defibrillators improve survival in end-stage renal disease: Results from a multi-center registry. Am J Nephrol 2010; 32(4): 305-10.
[15]
Chen TH, Wo HT, Chang PC, Wang CC, Wen MS, Chou CC. A meta-analysis of mortality in end-stage renal disease patients receiving implantable cardioverter defibrillators (ICDs). PLoS One 2014; 9(7): e99418.
[16]
Cheema A, Singh T, Kanwar M, et al. Chronic kidney disease and mortality in implantable cardioverter-defibrillator recipients. Cardiol Res Pract 2010; 2010: pii 989261.
[17]
Aggarwal A, Wang Y, Rumsfeld JS, Curtis JP, Heidenreich PA, Registry NCD. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm 2009; 6(11): 1565-71.
[18]
Charytan DM, Patrick AR, Liu J, et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011; 58(3): 409-17.
[19]
Parkash R. Complications from implantable cardioverter defibrillator implantation: Do the risks outweigh the benefits? Heart Rhythm 2009; 6(11): 1572-3.
[20]
Tompkins C, Mclean R, Cheng A, et al. End‐stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol 2011; 22(10): 1099-104.
[21]
Pavia S, Wilkoff B. The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. Curr Opin Cardiol 2001; 16(1): 66-71.
[22]
Fluck R, Wilson J, Davies J, Blackburn R, O’Donoghue D, Tomson C. UK Renal Registry 11th Annual Report (December 2008): Chapter 12 Epidemiology of methicillin resistant Staphylococcus aureus bacteraemia amongst patients receiving renal replacement therapy in England in 2007. Nephron Clin Pract 2009; 111(Suppl. 1): c247-56.
[23]
AL‐Khatib SM, Hellkamp AS, Lee KL, et al. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD‐HeFT). J Cardiovasc Electrophysiol 2008; 19(10): 1059-65.
[24]
Haines DE, Wang Y, Curtis J. Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantationclinical perspective. Circulation 2011; 123(19): 2069-76.
[25]
Buiten MS, De Bie MK, Van Der Heijden AC, et al. Chronic kidney disease and implantable cardioverter defibrillator related complications: 16 years of experience. J Cardiovasc Electrophysiol 2014; 25(9): 998-1004.
[26]
Jacob S, Bhandare D, Mathew A, Jahania MS. A Novel approach to ICD lead revision in a patient with extensive vascular thrombosis. Indian Pacing Electrophysiol J 2010; 10(2): 108.
[27]
Eberhardt F, Bode F, Bonnemeier H, et al. Long term complications in single and dual chamber pacing are influenced by surgical experience and patient morbidity. Heart 2005; 91(4): 500-6.
[28]
Dasgupta A, Montalvo J, Medendorp S, et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007; 49(5): 656-63.
[29]
Saad TF, Ahmed W, Davis K, Jurkovitz C. Cardiovascular implantable electronic devices in hemodialysis patients: Prevalence and implications for arteriovenous hemodialysis access interventions. Seminars in dialysis. 2015; Wiley Online Library; 2015. p. 94-100.
[30]
Drew DA, Meyer KB, Weiner DE. Transvenous cardiac device wires and vascular access in hemodialysis patients. Am J Kidney Dis 2011; 58(3): 494-6.
[31]
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346(12): 877-83.
[32]
Goudevenos JA, Reid PG, Adams PC, Holden MP, Williams DO. Pacemaker‐induced superior vena cava syndrome: Report of four cases and review of the literature. Pacing Clin Electrophysiol 1989; 12(12): 1890-5.
[33]
Asif A, Carrillo R, Garisto JD, et al. Epicardial cardiac rhythm devices for dialysis patients: minimizing the risk of infection and preserving central veins. Seminars in dialysis. 2012; Wiley Online Library; 2012. p. 88-94.
[34]
Bolad I, Karanam S, Mathew D, John R, Piemonte T, Martin D. Percutaneous treatment of superior vena cava obstruction following transvenous device implantation. Catheter Cardiovasc Interv 2005; 65(1): 54-9.
[35]
Chamorro H, Rao G, Wholey MH. Superior vena cava syndrome: A complication of transvenous pacemaker implantation 1. Radiology 1978; 126(2): 377-8.
[36]
Tokars JI, Light P, Anderson J, et al. A prospective study of vascular access infections at seven outpatient hemodialysis centers. Am J Kidney Dis 2001; 37(6): 1232-40.
[37]
Opelami O, Sakhuja A, Liu X, Tang WW, Schold JD, Navaneethan SD. Outcomes of infected cardiovascular implantable devices in dialysis patients. Am J Nephrol 2014; 40(3): 280-7.
[38]
de Oliveira JC, Martinelli M, Nishioka SADO, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2009; 2(1): 29-34.
[39]
Kennergren C. Management of cardiovascular implantable electronic devices infections in high-risk patients. Arrhythm Electrophysiol Rev 2015; 4(1): 53.
[40]
Guha A, Maddox WR, Colombo R, et al. Cardiac implantable electronic device infection in patients with end-stage renal disease. Heart Rhythm 2015; 12(12): 2395-401.
[41]
Bracke F. Complications and lead extraction in cardiac pacing and defibrillation. Neth Heart J 2008; 16(1): 27-30.
[42]
Asif A, Salman L, Lopera G, Haqqie SS, Carrillo R. Transvenous cardiac implantable electronic devices and hemodialysis catheters: Recommendations to curtail a potentially lethal combination. Seminars in dialysis. 2012; Wiley Online Library; 2012. p. 582-6.
[43]
Teruya TH, Abou-Zamzam AM, Limm W, Wong L, Wong L. Symptomatic subclavian vein stenosis and occlusion in hemodialysis patients with transvenous pacemakers. Ann Vasc Surg 2003; 17(5): 526-9.
[44]
Tan CS, Jie C, Joe J, et al. The impact of transvenous cardiac devices on vascular access patency in hemodialysis patients Seminars in dialysis; 2013: Wiley Online Library 2013; p. 728-32.
[45]
Asif A, Salman LH, Lopera GG, Carrillo RG. The dilemma of transvenous cardiac rhythm devices in hemodialysis patients: time to consider the epicardial approach? Kidney Int 2011; 79(12): 1267-9.
[46]
Asif A, Salman L, Carrillo RG, et al. ASDIN: Patency rates for angioplasty in the treatment of pacemaker‐induced central venous stenosis in hemodialysis patients: Results of a multi‐center study Seminars in dialysis 2009; Wiley Online Library; 2009. p. 671-6.
[47]
Dhamija RK, Tan H, Philbin E, et al. Subcutaneous implantable cardioverter defibrillator for dialysis patients: A strategy to reduce central vein stenoses and infections. Am J Kidney Dis 2015; 66(1): 154-8.
[48]
Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: This document was endorsed by the American Heart Association (AHA). Heart Rhythm 2009; 6(7): 1085-104.
[49]
Saad TF, Hentschel DM, Koplan B, et al. Cardiovascular implantable electronic device leads in CKD and ESRD patients: Review and recommendations for practice Seminars in Dialysis 2013; Wiley Online Library; 2013. p. 114-23.
[50]
Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death. Pacing Clin Electrophysiol 2004; 27(1): 4-9.
[51]
Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J Am Coll Cardiol 2010; 56(3): 194-203.
[52]
Adhyapak SM, Iyengar SS. Characteristics of a subset of patients with reversible systolic dysfunction in chronic kidney disease. Congest Heart Fail 2011; 17(3): 120-6.
[53]
EL‐Chami MF, Levy M, Kelli HM, et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end‐stage renal disease on dialysis. J Cardiovasc Electrophysiol 2015; 26(8): 900-4.
[54]
Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296(11): 1377-84.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2019
Page: [161 - 166]
Pages: 6
DOI: 10.2174/1573403X15666190118123754
Price: $58

Article Metrics

PDF: 50
HTML: 2